Update to Faron's Financial Calendar and Date of the Annual General Meeting in 2026

About this update from Faron Pharmaceuticals Oy

[{"type":"text","content":"TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company's financial calendar 2026.","length":279,"tagName":"p"},{"type":"text","content":"The Annual General Meeting is now planned to take place on 4 May 2026, instead of 30 March 2026 as previously communicated. Faron's Board of Directors will issue a separate company announcement in due course to formally convene the meeting.","length":244,"tagName":"p"},{"type":"text","content":"The publication date of Faron's half-year financial report for the period January 1 to June 30, 2026, remains unchanged being Wednesday 26 August 2026.","length":155,"tagName":"p"},{"type":"text","content":"For more information, please contact:","length":37,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"IR Partners, Finland(Media)Kare Laukkanen","length":43,"tagName":"p"}]},{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"+358 50 553 9535 / +44 7 469 766 [email protected]","length":65,"tagName":"p"}]}]},{"val":[{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"FINN Partners, US(Media) Alyssa Paldo","length":39,"tagName":"p"}]},{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"+1 847 791-8085 [email protected]","length":46,"tagName":"p"}]}]},{"val":[{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner","length":85,"tagName":"p"}]},{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"+44 (0) 207 213 0880","length":20,"tagName":"p"}]}]},{"val":[{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä","length":87,"tagName":"p"}]},{"style":"padding:1.5pt 3.0pt;","val":[{"type":"text","content":"+358 (0)40 555 4727+358 (0)50 553 8990","length":39,"tagName":"p"}]}]}],"length":424},{"type":"text","content":"About bexmarilimabBexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimi...

More updates from Faron Pharmaceuticals Oy